Vyxeos is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor, that is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) Vyxeos (daunorubicin and cytarabine) liposome for injection should be administered under the supervision of a qualified physician experienced in the uses of cancer chemotherapeutic agents.

Where can I buy Vyxeos?

Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its presence PAN India with over 20 years of domain experience.

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Vyxeos (daunorubicin and cytarabine) liposome for injection on prescription and Import License in Patient's Name only.

For Vyxeos or (daunorubicin and cytarabine) liposome for injection price in India.
Please contact +91 9811747774 or neeraj@indianpharmanetwork.co.in
Vyxeos (daunorubicin and cytarabine) liposome for injection

Get In Touch

Facilitator under Patient Assistance Programs In India

For Indian Patients, doctors and hospitals Vyxeos (daunorubicin and cytarabine) liposome for injection can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Dosage Forms and Strengths

For injection: 44 mg daunorubicin and 100 mg cytarabine encapsulated in liposomes as a lyophilized cake in a single-dose vial for reconstitution

ReadMore

FDA Approval Summary

Jazz Pharmaceuticals Announces FDA Approval of Vyxeos™ (daunorubicin and cytarabine) Liposome for Injection for the Treatment of Adults with Newly-Diagnosed Therapy-Related Acute Myeloid Leukemia (t-AML) or AML with Myelodysplasia-Related Changes (AML-MRC)
Aug 03, 2017,

ReadMore